CurQD as Add-On Therapy in Vedolizumab-Treated Ulcerative Colitis Patients: Retrospective Cohort Study

This study aims to evaluate whether adding CurQD, a nutraceutical composed of Curcumin and QingDai, improves treatment outcomes in patients with active ulcerative colitis (UC) who are already receiving Vedolizumab but still have ongoing disease activity. The study will use de-identified patient records collected through Evinature's global data platform. We will examine whether the addition of CurQD helps patients stay on Vedolizumab longer, improves symptoms and biomarkers, and increases satisfaction with treatment.

NCT Number	NCT07240168
Lead Sponsor	Evinature Ltd. Collaborators: Sheba Medical Center, Takeda Pharmaceuticals U.S.A., Inc.
Conditions	Ulcerative Colitis (UC)
Enrollment	400 participants
Start Date	2025-09-07
Primary Completion	2026-08-20 (estimated)
Study Completion	2026-08-20 (estimated)
Updated on ClinicalTrials.gov	2025-11-20